Á lódáil...
Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy
BACKGROUND: Infliximab is an effective therapy for inflammatory bowel disease (IBD). However, more than 50% of patients lose response. Empiric dose intensification is not effective for all patients because not all patients have objective disease activity or subtherapeutic drug level. The aim was to...
Na minha lista:
Foilsithe in: | Inflamm Bowel Dis |
---|---|
Main Authors: | , , , , , , , , , , |
Formáid: | Artigo |
Teanga: | Inglês |
Foilsithe: |
Lippincott Williams & Wilkins
2015
|
Ábhair: | |
Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4450916/ https://ncbi.nlm.nih.gov/pubmed/25989340 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MIB.0000000000000376 |
Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|